Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JNJ-38877618 (OMO-1)是一种口服有活性的 Met 激酶选择性抑制剂,其对野生型和突变体的 IC50值分别为2和3 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 498 | 现货 | ||
2 mg | ¥ 727 | 现货 | ||
5 mg | ¥ 1,390 | 现货 | ||
10 mg | ¥ 2,190 | 现货 | ||
25 mg | ¥ 3,680 | 现货 | ||
50 mg | ¥ 5,250 | 现货 | ||
100 mg | ¥ 7,180 | 现货 | ||
500 mg | ¥ 14,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,380 | 现货 |
产品描述 | JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively). |
靶点活性 | MET (WT):2 nM, MET (mutant):2 nM |
体外活性 | JNJ-38877618 shows nM potency against Met Ampl/mutant and therapy-resistant models. JNJ-38877618 has nM binding affinity (Kd=1.4 nM) and enzyme inhibitory activity against wt and M1268T mutant Met (2 and 3 nM IC50). Met inhibitory effects are assessed in proliferation, colony formation, and motility assays. |
体内活性 | JNJ-38877618 results in the regression of large Met amplified EBC-1 SqNSCLC where JNJ-38877618 leads to dose- and time-dependent inhibition of Met kinase activation, with the duration of target shut down considerably exceeding plasma exposure times. JNJ-38877618 causes complete inhibition of tumor growth in 3 models: the SNU5 Met amp gastric, U87-MG HGF autocrine glioblastoma, and Hs746T Met exon 14 skipping mutant gastric cancer. Combination treatments are well tolerated and improved EGFR targeted therapy[1]. |
别名 | OMO-1 |
分子量 | 374.35 |
分子式 | C20H12F2N6 |
CAS No. | 943540-74-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.5 mg/mL (12.02 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6713 mL | 13.3565 mL | 26.713 mL | 66.7824 mL |
5 mM | 0.5343 mL | 2.6713 mL | 5.3426 mL | 13.3565 mL | |
10 mM | 0.2671 mL | 1.3356 mL | 2.6713 mL | 6.6782 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
JNJ-38877618 943540-74-7 Tyrosine Kinase/Adaptors c-Met/HGFR OMO-1 JNJ 38877618 OMO 1 Inhibitor JNJ38877618 inhibit OMO1 inhibitor